AIM: To investigate the clinical efficacy and safety of intravitreal injection of triamcinolone combined macular grid photocoagulation treatment for macular edema.

METHODS: Totally 150 cases(150 eyes)with macular edema in our hospital from July 2009 to November 2013 were selected, which were randomly divided into study group(75 cases, 75 eyes)and control group(75 cases, 75 eyes). The cases in control group were treated with macular grid photocoagulation treatment, those in the study group used triamcinolone acetonide combined macular grid photocoagulation treatment. Best corrected visual acuity(BCVA), parallel optical coherence tomography(OCT)and fundus fluorescein angiography(FFA)were detected before treatment, after treatment 7d, 1, 3, and 9mo.

RESULTS:After the treatment, patients' vision were significantly improved in two groups(P<0.05). In the study group 7d, 1, 3, and 9mo after operation, the visual acuity was better than the control group and preoperative(P<0.05); fovea macular neurosensory layer thickness decreased significantly(P<0.05). In the control group, the point omentum macular neurosensory retinal thickness was not statistically significant at 7d, 1, 3, and 9mo after operation compared with before treatment(P>0.05). Fovea macular neurosensory retinal thickness in the study group was significantly lower than that in control group(P<0.05). Intraocular pressure of 7 cases in the study group increased slightly, and were normal after treatment.

CONCLUSION: Triamcinolone acetonide combined macular grid photocoagulation treatment is accurate, can effectively improve the visual acuity, reduce macular edema, it is safe and reliable, and suitable for clinical application.